Publications

Patients deserve better information on new drugs.

BMJ
Davis C, Wagner AK, Mintzes B, Scowcroft H, Woloshin S, Naci H

Financial toxicity of withdrawn poly (ADP-ribose) polymerase inhibitor indications for ovarian cancer.

Value Health
Dottino JA, Esselen KM, Costa R, Argetsinger S, Shahzad M, Ross-Degnan D, Wagner AK

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.

J Pharm Policy Pract
Shahzad M, Naci H, Esselen KM, Dottino JA, Wagner AK

Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.

Lancet Oncol
Naci H, Zhang Y, Woloshin S, Guan X, Xu Z, Wagner AK

Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.

Lancet Reg Health West Pac
Wei Y, Zhang Y, Xu Z, Wang G, Zhou Y, Li H, Shi L, Naci H, Wagner AK, Guan X

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021.

BMJ Glob Health
Zhou Y, Naci H, Chen D, Bai L, Shi L, Guan X, Wagner AK

Changing Tides? Anticancer Biologic and Biosimilar Use in Medicare Part B, 2019-2021.

JCO Oncol Pract
McClean AR, Wagner AK, Lu CY

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.

J Glob Health
Yang Y, Zhang Y, Wagner AK, Li H, Shi L, Guan X

Impact of a national antibiotic stewardship intervention in China targeting carbapenem overuse: an interrupted time-series analysis.

Int J Antimicrob Agents
Xu S, Kitchen C, Liu Y, Kabba JA, Hayat K, Wang X, Wang G, Zhang F, Chang J, Fang Y, Wagner AK, Ross-Degnan D

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis.

Lancet Reg Health Am
Ivama-Brummell AM, Marciniuk FL, Wagner AK, Osorio-de-Castro CGS, Vogler S, Mossialos E, Tavares-de-Andrade CL, Naci H

Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe.

BMJ
Davis C, Wagner AK, Salcher-Konrad M, Scowcroft H, Mintzes B, Pokorny AMJ, Lew J, Naci H

The Effectiveness of Enhanced Primary Healthcare (EnPHC) interventions on Type 2 diabetes management in Malaysia: Difference-in-differences (DID) analysis.

Prim Care Diabetes
Husin M, Teh XR, Ong SM, Lim YMF, Ang SH, Chan CL, Lim MT, Shanmugam S, Khamis N, Jaafar FSA, Ibrahim NI, Nasir NH, Kusuma D, Wagner AK, Ross-Degnan D, Atun R, Sivasampu S

Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway.

JAMA
Shahzad M, Naci H, Wagner AK

Newly approved cancer drugs in China - innovation and clinical benefit.

Nat Rev Clin Oncol
Zhang Y, Wagner AK, Guan X

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.

JAMA Netw Open
Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X

New-onset cancer cases in FDA's Sentinel System: a large distributed system of US electronic healthcare data.

Cancer Epidemiol Biomarkers Prev
Haug NR, Wagner AK, McGlynn KA, Leonard CE, Nguyen MD, Major JM

Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil.

BMJ Glob Health
Ivama-Brummell AM, Wagner AK, Pepe VLE, Naci H

Use of Palliative Care Among Commercially Insured Patients With Metastatic Cancer Between 2001 and 2016.

JCO Oncol Pract
Ferrario A, Zhang F, Ross-Degnan D, Wharam JF, Twaddle ML, Wagner AK

Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval

Shahzad M, Naci H, Wagner AK.